Peer-reviewed veterinary case report
Dog with stage III mouth cancer improved after PD-1 antibody treatment
By Xu, Shuo et al.·Published in Frontiers in veterinary science·2023·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report.
- Species:
- dog
Plain-English summary
An 11-year-old male border collie was brought in for a large mass on the left side of his neck. After tests, the mass was found to be an aggressive type of cancer called adenocarcinoma, likely from a salivary gland. The dog was treated with a special antibody that targets cancer cells, and after two months, the tumor showed signs of shrinking and remained stable for six months. Sadly, the dog was later euthanized for unrelated reasons, but he lived for 316 days after starting treatment, showing a positive response to this new therapy.
People also search for: dog neck mass treatment · border collie cancer survival · PD-1 antibody for dog cancer
Abstract
Monoclonal antibody targeting programmed cell death-1 (PD-1) is one of the most promising treatment therapies for human cancers. Canine PD-1 antibodies used in clinical trials have also shown efficacy in treating canine cancers. An 11-year-old male intact border collie presented to us for evaluation of left cervical mass. Computed tomography (CT) examination revealed an irregular pharyngeal mass invading the surrounding soft tissue. Histological and immunohistochemical results were consistent with a diagnosis of adenocarcinoma, most likely originating from the minor salivary gland. An anti-canine PD-1 monoclonal antibody was administered. Two months after the initial treatment, the tumor reached partial remission and maintained as such for 6 months. Finally, the patient was euthanized due to reasons unrelated to cancer, with a survival time of 316 days. To our knowledge, this is the first report of response to PD-1 blockade treatment in canine adenocarcinoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37252387/